Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
数据显示，研究性zolbetuximab将疾病进展或死亡风险降低了24.9% 研究对Claudin...
Read more about 安斯泰来在2023年美国临床肿瘤学会（ASCO）胃肠道肿瘤研讨会上展示Zolbetuximab三期试验积极研究结果
东京，2023年1月19日 -...
近日，安斯泰来中国凭借2022年在公益事业方面的突出表现，再次斩获多个公益奖项。凭借“改变明天”的公益项目，安斯泰来已经连续两年上榜“CSRC...
-该组合有可能成为在这种治疗场景中结合抗体药物偶联物和免疫疗法的首个治疗选择-...
Follow China news
